Antonio Jimeno

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. pmc The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas
    Ryan T Anderson
    Corresponding Author Antonio Jimeno, University of Colorado School of Medicine, MS8117, 12801 East 17th Avenue, Room L18 8101B, Aurora, CO 80045
    Mol Cancer Ther 12:1994-2005. 2013
  2. doi Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer
    D W Bowles
    University of Colorado School of Medicine, Division of Medical Oncology, and Denver Veterans Affairs Medical Center, Denver, Colorado, USA
    Drugs Today (Barc) 49:523-35. 2013
  3. doi Trametinib for the treatment of melanoma
    N Alluri
    Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Drugs Today (Barc) 49:491-8. 2013
  4. doi Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
    V Narayanan
    Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
    Drugs Today (Barc) 49:447-56. 2013
  5. pmc Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
    Antonio Jimeno
    University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    Clin Cancer Res 19:2766-74. 2013
  6. doi Tivozanib: practical implications for renal cell carcinoma and other solid tumors
    E M Berge
    University of Colorado School of Medicine, Denver, CO, USA
    Drugs Today (Barc) 49:303-15. 2013
  7. ncbi Dabrafenib in the treatment of advanced melanoma
    T Medina
    Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Drugs Today (Barc) 49:377-85. 2013
  8. doi Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    V Narayanan
    Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
    Drugs Today (Barc) 49:261-9. 2013
  9. doi The development of regorafenib and its current and potential future role in cancer therapy
    S L Davis
    Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, Colorado, USA
    Drugs Today (Barc) 49:105-15. 2013
  10. doi Axitinib, a new therapeutic option in renal cell carcinoma
    E R Kessler
    University of Colorado School of Medicine, Division of Medical Oncology, Denver, Colorado 80045, USA
    Drugs Today (Barc) 48:633-44. 2012

Detail Information

Publications35

  1. pmc The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas
    Ryan T Anderson
    Corresponding Author Antonio Jimeno, University of Colorado School of Medicine, MS8117, 12801 East 17th Avenue, Room L18 8101B, Aurora, CO 80045
    Mol Cancer Ther 12:1994-2005. 2013
    ..Although consistent inhibition of the PI3K pathway was not evident in HNSCC, we identified a combination of PI3K/TP53 events necessary, but not sufficient, for rigosertib sensitivity...
  2. doi Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer
    D W Bowles
    University of Colorado School of Medicine, Division of Medical Oncology, and Denver Veterans Affairs Medical Center, Denver, Colorado, USA
    Drugs Today (Barc) 49:523-35. 2013
    ..It is also under investigation in multiple other tumor types. This review will stress on afatinib's preclinical pharmacology, pharmacokinetics and clinical activity with a focus on NSCLC. ..
  3. doi Trametinib for the treatment of melanoma
    N Alluri
    Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Drugs Today (Barc) 49:491-8. 2013
    ..Preclinical data and limited clinical data suggest that MEK inhibitors may be a component of effective therapy for a broad spectrum of cancers with other oncogenic drivers. ..
  4. doi Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia
    V Narayanan
    Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
    Drugs Today (Barc) 49:447-56. 2013
    ..This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of omacetaxine mepesuccinate in the current milieu of tyrosine kinase inhibitor-dominant therapy of chronic myeloid leukemia. ..
  5. pmc Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
    Antonio Jimeno
    University of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    Clin Cancer Res 19:2766-74. 2013
    ....
  6. doi Tivozanib: practical implications for renal cell carcinoma and other solid tumors
    E M Berge
    University of Colorado School of Medicine, Denver, CO, USA
    Drugs Today (Barc) 49:303-15. 2013
    ..This review focuses on the preclinical development, pharmacokinetics and early clinical activity of tivozanib in renal cell carcinoma and other solid tumors...
  7. ncbi Dabrafenib in the treatment of advanced melanoma
    T Medina
    Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA
    Drugs Today (Barc) 49:377-85. 2013
    ..The U.S. Food and Drug Administration has recently approved dabrafenib as a single agent for the treatment of unresectable or metastatic melanoma in adult patients with BRAF V600E mutation. ..
  8. doi Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    V Narayanan
    Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
    Drugs Today (Barc) 49:261-9. 2013
    ..This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive adult acute lymphoblastic leukemia...
  9. doi The development of regorafenib and its current and potential future role in cancer therapy
    S L Davis
    Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, Colorado, USA
    Drugs Today (Barc) 49:105-15. 2013
    ..This review will focus on the development of regorafenib, from early preclinical work through phase I, II and III trials, as well as highlighting the current role and potential future directions of this novel agent...
  10. doi Axitinib, a new therapeutic option in renal cell carcinoma
    E R Kessler
    University of Colorado School of Medicine, Division of Medical Oncology, Denver, Colorado 80045, USA
    Drugs Today (Barc) 48:633-44. 2012
    ..This review will focus on the preclinical pharmacology, pharmacokinetics and clinical activity of this agent, and describe its place in the current treatment of renal cell carcinoma...
  11. doi Vismodegib in basal cell carcinoma
    R N Amaria
    Cutaneous Malignancies and Developmental Therapeutics Programs, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Drugs Today (Barc) 48:459-67. 2012
    ..In January 2012, vismodegib was approved by the FDA for the treatment of unresectable or metastatic basal cell carcinomas of the skin...
  12. doi Crizotinib for the treatment of patients with advanced non-small cell lung cancer
    D W Bowles
    University of Colorado School of Medicine, Division of Medical Oncology, Aurora, Colorado 80045, USA
    Drugs Today (Barc) 48:271-82. 2012
    ..In August 2011, crizotinib was approved for the treatment of advanced ALK-positive NSCLC...
  13. doi Vemurafenib: the road to personalized medicine in melanoma
    R N Amaria
    University of Colorado Cancer Center, Aurora, CO, USA
    Drugs Today (Barc) 48:109-18. 2012
    ....
  14. ncbi KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection
    Antonio Jimeno
    Medical Oncology Division, PO Box 6511, MS 8117, Aurora, CO, 80045, USA
    J Clin Oncol 27:1130-6. 2009
    ....
  15. doi KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer
    Antonio Jimeno
    University of Colorado Cancer Center, Denver, CO, USA
    Cancer J 15:110-3. 2009
    ..In this article, we will review the available clinical data and discuss the implications for future drug development in colorectal cancer...
  16. doi Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer
    Wen Wee Ma
    Roswell Park Cancer Institute, Buffalo, New York University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Cancer Res 18:2048-55. 2012
    ..This phase I study aimed to determine the recommended phase II dose (RPTD) of the combination of rigosertib and gemcitabine in patients with cancer...
  17. pmc A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
    Stephen B Keysar
    Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine UCSOM, Aurora, CO 80045, United States
    Mol Oncol 7:776-90. 2013
    ..This model enables to prospectively test therapeutic-oriented hypotheses leading to personalized medicine...
  18. pmc Patient-derived tumour xenografts as models for oncology drug development
    John J Tentler
    Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, 12801 East 17th Avenue, Aurora, CO 80045, USA
    Nat Rev Clin Oncol 9:338-50. 2012
    ....
  19. pmc Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer
    Stephen B Keysar
    Division of Medical Oncology, Department of Medicine, Departments of Pharmacology, Pathology, Radiation Oncology, and Otolaryngology, University of Colorado School of Medicine, Aurora, CO 80045, USA
    Cancer Res 73:3381-92. 2013
    ..Cetuximab plus IPI-926 forces tumor cells into an EGFR-dependent state, delaying or completely blocking tumor recurrence...
  20. pmc KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer
    Wilbur A Franklin
    Department of Pathology, University of Colorado Denver, Fitzsimons Campus, 12801 E 17 Ave, Aurora, CO 80045, USA
    J Mol Diagn 12:43-50. 2010
    ..We conclude that coring of the paraffin blocks and testing by ARMS/S is a sensitive, specific, and efficient method for KRAS testing...
  21. pmc Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
    Colin D Weekes
    University of Colorado Cancer Center, 12801 E 17th Avenue, RC 1 South, Rm 8123, MS 8117, Aurora, CO 80045, USA
    Invest New Drugs 29:1057-65. 2011
    ..Lastly, TYMS, ATM and RecQ1 single nucleotide polymorphism were analyzed relative to overall survival in patients screened for study participation...
  22. ncbi Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies
    Daniel W Bowles
    Authors Affiliations Department of Medicine, Division of Medical Oncology Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado and Onconova Therapeutics Inc, Newtown, Pennsylvania
    Clin Cancer Res 20:1656-65. 2014
    ....
  23. doi Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
    Ignace B Vergote
    Ignace B Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO Florence Joly, Centre François Baclesse Caen, Caen Anne Lesoin, Centre Oscar Lambret, Lille Isabelle Ray Coquard, Centre Leon Berard, Lyon Laure Favier, Centre Georges Francois Leclerc, Dijon Hervé Curé, Unicancer Institut Jean Godinot, Reims Eric Pujade Lauraine, Hopital Hotel Dieu, Paris, France Dionyssios Katsaros, University of Turin Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin Nicoletta Colombo, University of Milan Bicocca and Istituto Europeo di Oncologia, Milan, Italy Christian Marth, Medical University of Innsbruck, Innsbruck Alexander Reinthaller, Medical University of Vienna, Vienna, Austria Marcia Hall, Mount Vernon Cancer Centre, Middlesex John Green, University of Liverpool, University of Kent
    J Clin Oncol 32:320-6. 2014
    ..This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy...
  24. pmc Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer
    Wells A Messersmith
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Clin Colorectal Cancer 9:297-304. 2010
    ..Bevacizumab was later included as standard of care at the MTD...
  25. doi Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer
    Kyle E Rusthoven
    University of Colorado Comprehensive Cancer Center, Aurora, CO 80045 0508, USA
    Int J Radiat Oncol Biol Phys 78:1020-5. 2010
    ..To present the first report of a Phase I trial evaluating concurrent and maintenance erlotinib and reirradiation in patients with recurrent or secondary primary head-and-neck cancer (HNC)...
  26. doi New phosphatidylinositol 3-kinase inhibitors for cancer
    Daniel W Bowles
    University of Colorado Comprehensive Cancer Center, Aurora, CO 80045, USA
    Expert Opin Investig Drugs 20:507-18. 2011
    ..The PI3K signaling axis is an important pathway involved in myriad human malignancies. Inhibition of this axis is a promising therapeutic approach for several cancers...
  27. pmc Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
    Wells A Messersmith
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Cancer Chemother Pharmacol 63:181-8. 2008
    ..To determine the maximum tolerated dose (MTD) of trabectedin plus gemcitabine administered on a weekly schedule in patients with advanced solid tumors...
  28. ncbi JAK2 inhibition for the treatment of hematologic and solid malignancies
    Brian L Harry
    University of Colorado School of Medicine, Medical Scientist Training Program, Aurora, CO 80045, USA
    Expert Opin Investig Drugs 21:637-55. 2012
    ..In the past several years, JAK2 inhibitors have been rapidly developed as targeted therapies for MPNs...
  29. pmc More than markers: biological significance of cancer stem cell-defining molecules
    Stephen B Keysar
    University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Mol Cancer Ther 9:2450-7. 2010
    ..Instead of looking solely at the marker expression in these populations, we hope to clarify the biologically significant roles these markers and activities play in tumor progression, metastases, and as possible targets for therapy...
  30. ncbi The intersection between cannabis and cancer in the United States
    Daniel W Bowles
    Developmental Therapeutics Program, University of Colorado Cancer Center, Aurora, CO 80045, USA
    Crit Rev Oncol Hematol 83:1-10. 2012
    ....
  31. doi BRCA in breast cancer: from risk assessment to therapeutic prediction
    Jennifer R Diamond
    Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, University of Colorado at Denver Anschutz Medical Campus, Aurora, Colorado, USA
    Drug News Perspect 22:603-8. 2009
    ..BRCA1/2 mutation or functional loss will likely serve as a useful predictive biomarker of response to treatment with PARP inhibitors...
  32. ncbi Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation
    Daniel W Bowles
    Division of Medical Oncology, University of Colorado School of Medicine, CO, USA
    Future Oncol 10:1065-80. 2014
    ....
  33. pmc Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas
    Jacob Minor
    Department of Otolaryngology, University of Colorado Denver, Aurora, CO, USA
    Oral Oncol 48:73-8. 2012
    ..In addition, miR-9 may function as a tumor suppressor in HNSCC through inhibition of cell proliferation and elevation of tumor suppressor PTEN...
  34. doi Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
    Wells A Messersmith
    Gastrointestinal Medical Oncology Program, University of Colorado Cancer Center, 12801 East 17th Avenue, Aurora, CO 80045, USA
    Mol Cancer Ther 8:1484-93. 2009
    ..These results may aid the clinical development of bosutinib and other Src inhibitors in pancreas cancer...
  35. ncbi Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis
    Wells Messersmith
    Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 4:1381-6. 2005
    ..Colorectal tumors show higher staining of pEGFR and downstream effectors compared to matched normal colorectal tissues...

Research Grants1

  1. Hedgehog signaling in head and neck cancer stem cells, and its role in resistance
    Antonio Jimeno; Fiscal Year: 2010
    ..We will also seek ways to determine what patients will benefit from these drugs, to individualize caner therapy. ..